Back to results
US 2006/0189586 A1Published application
Pharmaceutical compositions comprising active vitamin D compounds
OwnerJeffrey Clelandinventor
Life of this patent
Estimating the term…
Abstract
Disclosed are pharmaceutical compositions comprising an active vitamin D compound in emulsion pre-concentrate formulations, as well as emulsions and sub-micron droplet emulsions produced therefrom. The compositions comprise a lipophilic phase component, one or more surfactants, and an active vitamin D compound. The compositions may optionally further comprise a hydrophilic phase component.
Claims35
A pharmaceutical composition comprising:
- (a) a lipophilic phase component,
- (b) one or more surfactants, and
- (c) an active vitamin D compound;
- wherein said composition comprises one of the following combinations of lipophilic phase component and one or more surfactants, wherein the percentage of each component is by weight based upon the total weight of the composition excluding the active vitamin D compound:
- a.
- Gelucire 44/14
- about 50%
- MIGLYOL 812
- about 50%;
- b.
- Gelucire 44/14
- about 50%
- Vitamin E TPGS
- about 10%
- MIGLYOL 812
- about 40%;
- c.
- Gelucire 44/14
- about 50%
- Vitamin E TPGS
- about 20%
- MIGLYOL 812
- about 30%;
- d.
- Gelucire 44/14
- about 40%
- Vitamin E TPGS
- about 30%
- MIGLYOL 812
- about 30%;
- e.
- Gelucire 44/14
- about 40%
- Vitamin E TPGS
- about 20%
- MIGLYOL 812
- about 40%;
- f.
- Gelucire 44/14
- about 30%
- Vitamin E TPGS
- about 30%
- MIGLYOL 812
- about 40%;
- g.
- Gelucire 44/14
- about 20%
- Vitamin E TPGS
- about 30%
- MIGLYOL 812
- about 50%;
- h.
- Vitamin E TPGS
- about 50%
- MIGLYOL 812
- about 50%;
- i.
- Gelucire 44/14
- about 60%
- Vitamin E TPGS
- about 25%
- MIGLYOL 812
- about 15%;
- j.
- Gelucire 50/13
- about 30%
- Vitamin E TPGS
- about 5%
- MIGLYOL 812
- about 65%;
- k.
- Gelucire 50/13
- about 50%
- MIGLYOL 812
- about 50%;
- l.
- Gelucire 50/13
- about 50%
- Vitamin E TPGS
- about 10%
- MIGLYOL 812
- about 40%;
- m.
- Gelucire 50/13
- about 50%
- Vitamin E TPGS
- about 20%
- MIGLYOL 812
- about 30%;
- n.
- Gelucire 50/13
- about 40%
- Vitamin E TPGS
- about 30%
- MIGLYOL 812
- about 30%;
- o.
- Gelucire 50/13
- about 40%
- Vitamin E TPGS
- about 20%
- MIGLYOL 812
- about 40%;
- p.
- Gelucire 50/13
- about 30%
- Vitamin E TPGS
- about 30%
- MIGLYOL 812
- about 40%;
- q.
- Gelucire 50/13
- about 20%
- Vitamin E TPGS
- about 30%
- MIGLYOL 812
- about 50%;
- r.
- Gelucire 50/13
- about 60%
- Vitamin E TPGS
- about 25%
- MIGLYOL 812
- about 15%;
- s.
- Gelucire 44/14
- about 50%
- PEG 4000
- about 50%;
- t.
- Gelucire 50/13
- about 50%
- PEG 4000
- about 50%;
- u.
- Vitamin E TPGS
- about 50%
- PEG 4000
- about 40%;
- v.
- Gelucire 44/14
- about 33.3%
- Vitamin E TPGS
- about 33.3%
- PEG 4000
- about 33.3%;
- w.
- Gelucire 50/13
- about 33.3%
- Vitamin E TPGS
- about 33.3%
- PEG 4000
- about 33.3%;
- x.
- Gelucire 44/14
- about 50%
- Vitamin E TPGS
- about 50%;
- y.
- Gelucire 50/13
- about 50%
- Vitamin E TPGS
- about 50%;
- z.
- Vitamin E TPGS
- about 5%
- MIGLYOL 812
- about 95%;
- aa.
- Vitamin E TPGS
- about 5%
- MIGLYOL 812
- about 65%
- PEG 4000
- about 30%;
- ab.
- Vitamin E TPGS
- about 10%
- MIGLYOL 812
- about 90%;
- ac.
- Vitamin E TPGS
- about 5%
- MIGLYOL 812
- about 85%
- PEG 4000
- about 10%;
- and
- ad.
- Vitamin E TPGS
- about 10%
- MIGLYOL 812
- about 80%
- PEG 4000
- about 10%.
192 more elements
A pharmaceutical composition comprising an active vitamin D compound, about 50% MIGLYOL 812, about 50% vitamin E TPGS, about 0.35% butylated hydroxy anisole (BHA), and about 0.35% butylated hydroxytoluene (BHT).
Dependencies are inferred from the claim text.